PRECLINICAL RESEARCH

The platform supports investigators in their preclinical research, handling different phases of a project from conception to acquisition realization, image analysis, and co-writing articles.

The preclinical imaging platform covers multiple domains (oncology, cardiology, neurology, inflammation, etc.).

It includes:

  • A certified conventional A1 type animal facility, accommodating study animals (rats, mice) in ventilated cabinets controlled daily.
  • A dedicated area for surgical procedures, equipped with physiological monitoring devices and beds suitable for working under Specific Pathogen-Free (SPF) conditions.
  • A room for cell culture studies to conduct in vitro radiotracer biodistribution on cells before animal injection.
  • Facilities and equipment for in vivo exams with an animal-dedicated PET/CT scanner (Inviscan).
  • Facilities and dedicated equipment for ex vivo analyses on tissue sections (autohistoradiography device; CR 35 Bio plus) and/or blood or organ samples (gamma counter).
  • An animal welfare structure (SBEA) working closely with a referring veterinarian to continually improve animal refinement.

Nancyclotep has conducted over 62 preclinical studies since 2008.

Nancyclotep

NEW: HERO PLATFORM


The HERO platform aims to structure an ex vivo screening platform on preserved frozen or fresh human tissues to assess early tissue binding of experimental radiolabeled molecules (antibodies, peptides, nanobodies) using autoradiography.

The main objective is to document the binding specificity of these ligands on tumor, inflammatory, or healthy tissues, in an ethical and translational approach, in line with the 3Rs principles of good laboratory practices (Replacement, Reduction, Refinement of animal use).